This research study is looking at molecular predictors of cancer in patients at high risk of lung cancer. Using samples of blood, urine, sputum, and lung tissue from patients at high risk of cancer for laboratory studies may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
| Study Type : | Observational |
| Estimated Enrollment : | 2000 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Official Title: | Molecular Predictors of Lung Cancer Behavior |
| Study Start Date : | December 2003 |
| Estimated Primary Completion Date : | January 31, 2025 |
| Estimated Study Completion Date : | January 31, 2025 |
Contacts
| Contact: Vanderbilt Ingram Clinical Trials Information Program | 1-800-811-8480 |
Locations
| United States, Tennessee | |
| Vanderbilt-Ingram Cancer Center | Recruiting |
| Nashville, Tennessee, United States, 37212 | |
| Contact: VICC Clinical Trials Information Program 800-811-8480 cip@vanderbilt.edu | |
| Principal Investigator: Pierre Massion, MD | |
| Veterans Affairs Medical Center – Nashville | Recruiting |
| Nashville, Tennessee, United States, 37212 | |
| Contact: Research Office 615-873-8066 | |
| Contact: Rena Burns, RN (615) 873-7658 Rena.Burns@va.gov | |
| Principal Investigator: Pierre Massion, MD | |
| ClinicalTrials.gov Identifier: | NCT00898313 |
